Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636690 | 0.82 | SCN8A (0.49) | FFAR1SCN8ACASRMPOFFAR4 | |
| SCHEMBL13447590 | 0.80 | AGXT (0.61) | FFAR1FFAR4AGXT | |
| SCHEMBL12881753 | 0.79 | HTR7 (0.53) | FFAR1SCN8ACASRMPOFFAR4 | |
| SCHEMBL27362497 | 0.77 | CYP4F2 (0.50) | FFAR1FFAR4 | |
| SCHEMBL649159 | 0.75 | TSHR (0.46) | FFAR4AGXTPTPN1 | |
| SCHEMBL5990056 | 0.75 | HTR7 (0.51) | FFAR1SCN8ACASRMPODRD2 | |
| SCHEMBL4151331 | 0.75 | DRD2 (0.48) | FFAR1SCN8ACASRMPODRD2 | |
| SCHEMBL7500105 | 0.75 | DRD2 (0.48) | FFAR1SCN8ACASRMPODRD2 | |
| SCHEMBL10294624 | 0.74 | IDO1 (0.60) | AGXT | |
| SCHEMBL25453297 | 0.74 | CASR (0.51) | FFAR1SCN8ACASRMPODRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | FFAR1 298/4885SCN8A 3952/4885CASR 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.